Trial · NCT00820898

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00820898, Phase 2, Completed, Gynecologic Oncology Group; results first posted 2017-12-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer. Trials, record NCT00820898. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00820898

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT number: NCT00820898
Status: Completed
Phases: Phase 2
Enrollment: 24 participants, actual
Lead sponsor: Gynecologic Oncology Group
Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Interventions: Gemcitabine Hydrochloride
First posted: 2009-01-12
Last updated: 2017-12-29
Results first posted: 2017-12-05

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0	CT scan or MRI if used to follow lesion for measurable disease every other cycle until disease progression for up to 5 years.	RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above. Complete and partial responses are included in the objective tumor response rate.
Primary	Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	Assessed every cycle while on treatment, 30 days after the last cycle of treatment, and up to 5 years in follow-up

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0	CT scan or MRI if used to follow lesion for measurable disease every other cycle until disease progression for up to 5 years.	Eligible and treated patients	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	Assessed every cycle while on treatment, 30 days after the last cycle of treatment, and up to 5 years in follow-up	Eligible and treated patients	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group116

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0	Gemcitabine	Partial response	1	Participants
Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0	Gemcitabine	Complete response	0	Participants
Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	Grade 0	Leukopenia	6	Participants
Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	Grade 1 (CTCAE v 3.0)	Leukopenia	6	Participants
Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	Grade 2 (CTCAE v 3.0)	Leukopenia	8	Participants
Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	Grade 3 (CTCAE v 3.0)	Leukopenia	3	Participants
Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	Grade 4 (CTCAE v 3.0)	Leukopenia	0	Participants
Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	Grade 5 (CTCAE v 3.0)	Leukopenia	0	Participants
Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	Grade 0	Thrombocytopenia	5	Participants
Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	Grade 1 (CTCAE v 3.0)	Thrombocytopenia	11	Participants

1 to 10 of 116Source ClinicalTrials.gov

See all 116 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Gemcitabine	24
Overall Study	COMPLETED	Gemcitabine	23
Overall Study	NOT COMPLETED	Gemcitabine	1

Source ClinicalTrials.gov

Adverse events90

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Neutrophils	Blood and lymphatic system disorders	Gemcitabine	16	23
other	Platelets	Blood and lymphatic system disorders	Gemcitabine	20	23
other	Leukocytes	Blood and lymphatic system disorders	Gemcitabine	18	23
other	Lymphopenia	Blood and lymphatic system disorders	Gemcitabine	1	23
other	Hemoglobin	Blood and lymphatic system disorders	Gemcitabine	22	23
other	Pulmonary Hypertension	Cardiac disorders	Gemcitabine	1	23
other	Hypertension	Cardiac disorders	Gemcitabine	1	23
other	Hypotension	Cardiac disorders	Gemcitabine	1	23
other	Inr	Vascular disorders	Gemcitabine	1	23
other	Ptt	Vascular disorders	Gemcitabine	1	23

1 to 10 of 90Source ClinicalTrials.gov

See all 90 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Gemcitabine
Total, other adverse events	Gemcitabine	23	23
Total, serious adverse events	Gemcitabine	8	23

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA027469	Gynecologic Oncology Group	DISAIA, PHILIP J.	GYNECOLOGIC ONCOLOGY GROUP	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00820898

GET https://conductscience.org/api/trials/v1/NCT00820898/results?page=2

API reference For AI assistants